Pre-made Zuberitamab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zuberitamab is a biosimilar of rituximab [see Adis Insight Drug profile 800004275], a monoclonal antibody which targets CD20, being developed by Zhejiang Hisun Pharmaceutical, for the treatment of cancer, including diffuse large B-cell lymphoma.
| Products Name (INN Index) | Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
|---|---|
| INN Name | Zuberitamab |
| Target | MS4A1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 3bky:HL |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Zhejiang Hisun Pharmaceutical |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Diffuse large B-cell lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MS4A1 |
| Package |
